Momentum Biotechnologies and Axxam S.p.A. Announce Collaboration to Provide Unique Drug Discovery Solutions

Axxam S.p.A. and Momentum Biotechnologies have announced a partnership to provide unique drug discovery solutions for biotechnology and pharmaceutical clients. Through the partnership Axxam’s highly curated chemical diversity library, comprised of 325,000 compounds, will be available for high-throughput screening using Momentum’s mass spectrometry-based functional and binding assay platforms. Primary hits may be progressed in hit-to-lead projects and additional downstream experiments including testing in cell-based assays. 

Axxam is a leader in providing early drug discovery services, offering a wide range of applications in addition to an extensive chemical diversity library. The Axxam library was built using decades of broad screening experience and significant input from medicinal and computational chemists. The library is composed of small molecules carefully selected for quality and structural diversity.

Momentum Biotechnologies is a bioanalytical contract research organization (CRO) specializing in early drug discovery and offers mass spectrometry-based high-throughput functional and binding assays. Founded by the team that originally commercialized the RapidFire™ high-throughput mass spectrometry platform, the company has decades of screening and hit characterization experience.

“We are thrilled to enter this collaboration with Axxam” said Can Ozbal, CEO of Momentum. “Our clients will now have the option to access additional chemical matter for their drug discovery programs further enhancing our affinity selection mass spectrometry and functional assay services”. 

Axxam CEO Stefan Lohmer added “with this collaboration Axxam clients will now have access to mass spectrometry-based HTS and hit-to-lead technologies expanding upon the wide range of services existing within the Axxam portfolio.”

Author

Leave a Reply

Your email address will not be published.